Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Payables (2021 - 2025)

Prime Medicine (PRME) has disclosed Payables for 5 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 21.71% year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Dec 2025, down 21.71%, and an annual FY2025 reading of $8.9 million, down 21.71% over the prior year.
  • Payables was $8.9 million for Q4 2025 at Prime Medicine, down from $9.4 million in the prior quarter.
  • Across five years, Payables topped out at $19.5 million in Q4 2023 and bottomed at $1.4 million in Q4 2021.
  • Average Payables over 5 years is $7.5 million, with a median of $5.9 million recorded in 2023.
  • The sharpest move saw Payables skyrocketed 350.99% in 2023, then plummeted 41.9% in 2024.
  • Year by year, Payables stood at $1.4 million in 2021, then surged by 201.88% to $4.3 million in 2022, then surged by 350.99% to $19.5 million in 2023, then plummeted by 41.9% to $11.4 million in 2024, then fell by 21.71% to $8.9 million in 2025.
  • Business Quant data shows Payables for PRME at $8.9 million in Q4 2025, $9.4 million in Q3 2025, and $6.4 million in Q2 2025.